Harald Aamot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Harald Aamot has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Biljana Gigic
Department of General, Visceral, and Transplantation Surgery Heidelberg University Hospital Heidelberg Germany
1 shared publication - Christian Dominik Kohl
Universität Heidelberg
1 shared publication - Daniela Richter
Translational Oncology, German Cancer Research Center, Heidelberg, Germany
1 shared publication I. Karapanagiotou-Schenkel
1 shared publication- Petra Knaup
Institute of Medical Informatics, Heidelberg University, 69120 Heidelberg, Germany
1 shared publication U. Abel
1 shared publication
Latest Publications
- Open Access
- 24 July 2013
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 13 (1) , 75
Pseudonymization of patient identifiers for translational research
The usage of patient data for research poses risks concerning the patients’ privacy and informational self-determination. Next-generation-sequencing technologies and various other methods gain data from biospecimen, both for translational research and personalized medicine. If these biospecimen are anonymized, individual research results from genomic research, which should be offered to patients in a clinically relevant timeframe, cannot be associated back to the individual. This raises an ethical concern and challenges the legitimacy of anonymized patient samples. In this paper we present a new approach which supports both data privacy and the possibility to give feedback to patients about their individual research results.
- 24 July 2013
- Published by Springer Nature in BMC Medical Informatics and Decision Making
- Vol. 13 (1) , 75
Open AccessPseudonymization of patient identifiers for translational research
The usage of patient data for research poses risks concerning the patients’ privacy and informational self-determination. Next-generation-sequencing technologies and various other methods gain data from biospecimen, both for translational research and personalized medicine. If these biospecimen are anonymized, individual research results from genomic research, which should be offered to patients in a clinically relevant timeframe, cannot be associated back to the individual. This raises an ethical concern and challenges the legitimacy of anonymized patient samples. In this paper we present a new approach which supports both data privacy and the possibility to give feedback to patients about their individual research results.
- 1 July 2010
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 48 (07) , 476-477
Continuous monitoring of toxicity in clinical trials – simulating the risk of stopping prematurely
- 1 July 2010
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 48 (07) , 476-477
Continuous monitoring of toxicity in clinical trials – simulating the risk of stopping prematurely